Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Dariusz Rozkiewicz"'
Autor:
Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, Anna Krupa, Dariusz Pawlak
Publikováno v:
Molecules, Vol 28, Iss 5, p 2400 (2023)
In the last few decades, there has been a growing interest in Bruton’s tyrosine kinase (BTK) and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) signaling pathway and affects B-cell proliferation and differen
Externí odkaz:
https://doaj.org/article/53206f260dc24a97a4f5bef5f286917e
Autor:
Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Anna Tankiewicz-Kwedlo, Beata Sieklucka, Krystyna Pawlak, Robert Czarnomysy, Krzysztof Bielawski, Arkadiusz Surazynski, Joanna Kalafut, Alicja Przybyszewska, Mariusz Koda, Katarzyna Jakubowska, Adolfo Rivero-Muller, Dariusz Pawlak
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 35, Iss 1, Pp 1697-1711 (2020)
Recombinant human erythropoietin (Epo) is an effective and convenient treatment for cancer-related anaemia. In our study for the first time, we evaluated the effect of simultaneous use of Epo and Bruton’s tyrosine kinase (BTK) inhibitor LFM-A13 on
Externí odkaz:
https://doaj.org/article/418377d1f791473ea76404dcb6f5a02c
Autor:
Krzysztof Bielawski, Beata Sieklucka, Adolfo Rivero-Müller, Krystyna Pawlak, Anna Tankiewicz-Kwedlo, Dariusz Pawlak, Alicja Przybyszewska, Robert Czarnomysy, Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Joanna Kałafut, Mariusz Koda, Arkadiusz Surażyński, Katarzyna Jakubowska
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry
article-version (VoR) Version of Record
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 35, Iss 1, Pp 1697-1711 (2020)
article-version (VoR) Version of Record
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 35, Iss 1, Pp 1697-1711 (2020)
Recombinant human erythropoietin (Epo) is an effective and convenient treatment for cancer-related anaemia. In our study for the first time, we evaluated the effect of simultaneous use of Epo and Bruton’s tyrosine kinase (BTK) inhibitor LFM-A13 on
Publikováno v:
Cytokine. 62:75-80
Background YKL-40 is a new biomarker of inflammation, which is expressed by several cell types of the immune system. The aim of the present study was to evaluate plasma YKL-40 levels in hemodialysis (HD) patients and to establish its potential role a
Autor:
Justyna Magdalena Hermanowicz, Krystyna Pawlak, Arkadiusz Surażyński, Anna Tankiewicz-Kwedlo, Dariusz Rozkiewicz, Dariusz Pawlak, Tomasz Domaniewski, Wojciech Kwedlo
Publikováno v:
Current pharmaceutical biotechnology. 18(2)
Background: Cancer patients treated with alkylating agents and radiotherapy are exposed to high level of reactive oxygen species (ROS) in tissues. ROS can involve superoxide free radicals, peroxynitrite, singlet oxygen, nitric oxide and hydrogen pero
Autor:
Anna Pryczynicz, Justyna Magdalena Hermanowicz, Arkadiusz Surażyński, Krystyna Pawlak, Anna Tankiewicz-Kwedlo, Tomasz Domaniewski, Dariusz Pawlak, Andrzej Kemona, Dariusz Rozkiewicz
Publikováno v:
Molecular and Cellular Biochemistry
Anemia is a relatively common symptom coexisting with colorectal carcinoma. Besides having a positive impact on hematological parameters, erythropoietin (Epo) has the serious adverse effect of promoting the neoplastic process. The role of Epo in colo